| Literature DB >> 35524444 |
Abstract
A recent Phase II randomized, controlled trial of bumetanide as an adjunctive treatment for neonatal seizures showed a robust efficacy signal and no evidence of toxicity. Concerns regarding bumetanide as an adjunctive anticonvulsant are addressed here. An adequately powered multi-institutional trial is needed to accurately determine efficacy.Entities:
Keywords: GABA; bumetanide; chloride; neonatal seizures
Mesh:
Substances:
Year: 2022 PMID: 35524444 PMCID: PMC9283319 DOI: 10.1111/epi.17278
Source DB: PubMed Journal: Epilepsia ISSN: 0013-9580 Impact factor: 6.740